HIGHLIGHTS
SUMMARY
As a result, T_cells can no longer target those cancer cells. Anti-PD-1 antibodies prevent PD-1/PD-L1 binding, allowing T_cells to become active once more and fight the tumor. MSI-H/dMMR tumors are more easily recognized by tumor antigen-specific T_cells than those with MSI-L/MSS and/or proficient MMR (pMMR) tumors. Vascular endothelial growth factor (VEGF) inhibitors could modify the tumor microenvironment by increasing infiltrated CD8+ T_cells and PD-L1 expression in tumor cells. Some types of antiangiogenic multiple receptor tyrosine kinase inhibitors (RTKis) including regorafenib and lenvatinib . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.